{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"The TTP was defined as the time from the date of starting treatment until the date of first documented evidence of progression of disease or death.","groups":[{"description":"Bortezomib 1.3 milligram (mg) per meter\\^2 (m\\^2) bolus (a large amount) intravenous (into the vein) injection will be administered once daily on Days 1, 4, 8 and 11 of each 21-day cycle with addition of Dexamethasone 20 mg per day administered orally, once daily on Days 1 and 2, Days 4 and 5, Days 8 and 9 and Days 11 and 12 of each 21-day cycle as per Investigator's discretion for those participants who experience disease progression after treatment completion up to Cycle 2 or have no change from Baseline after completion of at least 4 cycles. The treatment will be given up to 8 cycles (24 weeks).","id":"OG000","title":"Bortezomib and Dexamethasone"}],"populationDescription":"The study was terminated. Due to insufficient number of participants, the outcome measure data was not analyzed.","reportingStatus":"POSTED","timeFrame":"Day 1 (Start of treatment) until the date of first documented evidence of progression of disease or death","title":"Time to Progression (TTP) of Disease","type":"SECONDARY"}